Aurobindo Pharma hives off biosimilar business to subsidiary

  • The decision was taken at the company’s board meeting on Wednesday, where it also finalised its earnings for the January-March quarter
  • The company also aims to improve operational efficiency of its business and is looking for a potential listing opportunity for the wholly-owned subsidiary in future

Leroy Leo
Updated3 Jun 2020, 09:30 PM IST
The company also aims to improve operational efficiency of its business and is looking for a potential listing opportunity for the wholly-owned subsidiary in future.
The company also aims to improve operational efficiency of its business and is looking for a potential listing opportunity for the wholly-owned subsidiary in future.(Mint)

Aurobindo Pharma on Wednesday said that it will hive off its biosimilars business to its one-month old wholy-owned subsidiary 'CuraTeQ Biologics Private Limited' for a cash consideration of 361.46 crore.

Biosimilars are biological medical products which are similar to existing medicines.

The decision was taken at the company’s board meeting on Wednesday, where it also finalised its earnings for the January-March quarter.

The Hyderabad-based drugmaker will transfer its biosimilars business, including related research and development and manufacturing facilities to its wholly-owned subsidiary.

The slump sale is aimed at increasing the focus towards biological R&D and its commercialization, as well as to augment fund raising and strategic tie-ups in future through joint ventures, among others, Aurobindo Pharma said in an exchange filing.

The company also aims to improve operational efficiency of its business and is looking for a potential listing opportunity for the wholly-owned subsidiary in future.

Aurobindo Pharma has been ramping ups its biosimilar operations for the last few years, a segment where an increasing number of drugmakers are entering for promise of strong returns.

The biosimilar business has a high gestation period and involves high risk, but also provides promise high returns as some of the biggest selling drugs globally are biologics.

In India, the biologics space is led by Biocon Ltd, which through its partnership with Mylan, has already commercialised the biosimilars trastuzumab, pegfilgrastim, among others.

Other players in the space include Dr Reddy’s Laboratories, Intas Pharmaceuticals, Zydus Cadila and Lupin.

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess
First Published:3 Jun 2020, 09:30 PM IST
HomeIndustryManufacturingAurobindo Pharma hives off biosimilar business to subsidiary

Most Active Stocks

Tata Steel

157.75
03:43 PM | 19 JUL 2024
-8.6 (-5.17%)

Tata Power

414.15
03:59 PM | 19 JUL 2024
-15.85 (-3.69%)

Bharat Electronics

306.30
03:45 PM | 19 JUL 2024
-7.2 (-2.3%)

Zee Entertainment Enterprises

137.55
03:57 PM | 19 JUL 2024
-4.9 (-3.44%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

Tata Teleservices Maharashtra

102.11
03:59 PM | 19 JUL 2024
4.68 (4.8%)

Rail Vikas Nigam

614.00
03:59 PM | 19 JUL 2024
27.65 (4.72%)

Jubilant Pharmova

752.25
03:43 PM | 19 JUL 2024
25.3 (3.48%)

One 97 Communications

458.70
03:55 PM | 19 JUL 2024
13.65 (3.07%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    76,272.000.00
    Chennai
    76,124.000.00
    Delhi
    75,533.000.00
    Kolkata
    75,089.000.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.76/L0.00
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsloanPremiumBudget